ピ・ブロマン
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2015/12/21 09:17:34」(JST)
[Wiki en表示]
Pipobroman
|
Systematic (IUPAC) name |
3-bromo-1-[4-(3-bromopropanoyl) piperazin-1-yl]-propan-1-one
|
Clinical data |
Trade names |
Vercite, Vercyte |
AHFS/Drugs.com |
International Drug Names |
Identifiers |
CAS Number |
54-91-1 Y |
ATC code |
L01AX02 |
PubChem |
CID: 4842 |
IUPHAR/BPS |
7271 |
DrugBank |
DB00236 Y |
ChemSpider |
4676 Y |
UNII |
6Q99RDT97R Y |
KEGG |
D00467 Y |
ChEMBL |
CHEMBL1585 Y |
Chemical data |
Formula |
C10H16Br2N2O2 |
Molecular mass |
356.054 g/mol |
SMILES
-
O=C(N1CCN(C(=O)CCBr)CC1)CCBr
|
InChI
-
InChI=1S/C10H16Br2N2O2/c11-3-1-9(15)13-5-7-14(8-6-13)10(16)2-4-12/h1-8H2 Y
-
Key:NJBFOOCLYDNZJN-UHFFFAOYSA-N Y
|
(verify) |
Pipobroman (trade names Vercite, Vercyte) is an anti-cancer drug that probably acts as an alkylating agent.[1] It is marketed by Abbott Laboratories.[2]
References
- ^ Passamonti, F.; Lazzarino, M. (2003). "Treatment of Polycythemia Vera and Essential Thrombocythemia: The Role of Pipobroman". Leukemia & Lymphoma 44 (9): 1483–1488. doi:10.3109/10428190309178768. PMID 14565648.
- ^ Drugs.com: Pipobroman
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
English Journal
- Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study.
- Tefferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi AM, Rodeghiero F, Randi ML, Vaidya R, Cazzola M, Rambaldi A, Gisslinger B, Pieri L, Ruggeri M, Bertozzi I, Sulai NH, Casetti I, Carobbio A, Jeryczynski G, Larson DR, Müllauer L, Pardanani A, Thiele J, Passamonti F, Barbui T.SourceDivision of Hematology, Department of Medicine, Clinic, Rochester, MN, USA.
- Leukemia.Leukemia.2013 Sep;27(9):1874-81. doi: 10.1038/leu.2013.163. Epub 2013 Jun 6.
- Under the auspices of an International Working Group, seven centers submitted diagnostic and follow-up information on 1545 patients with World Health Organization-defined polycythemia vera (PV). At diagnosis, median age was 61 years (51% females); thrombocytosis and venous thrombosis were more frequ
- PMID 23739289
- An unknown cause of aortic valve stenosis: polycythemia vera.
- Fazio G, Caracciolo C, Barone R, D'angelo L, Di Maggio R, Vernuccio F, Siragusa S.SourceMedical Clinic Riabiliter, Via Albiri 3, 90100 Palermo, Italy.
- Journal of thrombosis and thrombolysis.J Thromb Thrombolysis.2013 Feb;35(2):282-5. doi: 10.1007/s11239-012-0786-7.
- Polycythemia vera (PV) is a chronic myeloproliferative disorder characterized by an abnormal increase in red blood cells. The involvement of the heart during the course of the illness represents a common cause of morbidity and it is linked to an increased thrombogenic risk subsequent to higher blood
- PMID 22843194
- Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980.
- Kiladjian JJ, Chevret S, Dosquet C, Chomienne C, Rain JD.SourceHôpital Saint-Louis, AP-HP, 1 avenue Claude Vellefaux, Paris, France. jean-jacques.kiladjian@sls.aphp.fr
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology.J Clin Oncol.2011 Oct 10;29(29):3907-13. doi: 10.1200/JCO.2011.36.0792. Epub 2011 Sep 12.
- PURPOSE: The overall impact of hydroxyurea (HU) or pipobroman treatments on the long-term outcome of patients with polycythemia vera (PV) has not been assessed in randomized studies. We report final analyses from the French Polycythemia Study Group (FPSG) study, which randomly assigned HU versus pip
- PMID 21911721
Japanese Journal
- Acute myeloid leukemia (AML) having evolved from essential thrombocythemia (ET) : distinctive chromosome abnormalities in patients treated with pipobroman or hydroxyurea
- 13年の経過後,急性リンパ性白血病を発症した真性赤血球増加症
- 新井 ゆかり,増田 道彦,岡村 隆光,和田 眞紀夫,泉二 登志子,溝口 秀昭
- 臨床血液 37(12), 1405-1409, 1996
- 症例は54歳,女性。1981年近医で白血球増多を指摘され,1982年2月当科初診となった。汎血球増加症,好中球アルカリホスファターゼ指数高値,血清ビタミンB12高値,循環赤血球量増加,脾腫などから真性赤血球増加症(PV)と診断した。瀉血と,一時期ピポブロマンあるいはヒドロキシカルバミドで加療していた。1995年8月に,脾腫増悪と末梢血中に芽球出現し,急性白血病の合併が疑われ入院となった。入院時の理 …
- NAID 130004500226
- 真性赤血球増加症の経過中に発症し,DICで死亡した巨核芽球性白血病
- 日野 研一郎,佐藤 聖哲,坂下 暁子,友安 茂,鶴岡 延熹,小池 正
- 臨床血液 33(4), 500-506, 1992
- … 真性赤血球増加症の診断のもとにpipobroman, carbazilquinon, busulfanの投与を受けていたが,診断10年後,発熱,貧血,血小板減少のため再入院した。 …
- NAID 130004919139
Related Links
- Publications, Research Topics, Scientific Experts about pipobroman ... Polycythemia vera (PV) is a myeloproliferative disorder, characterized by the expansion of the red cell mass. Our purpose was to evaluate the efficacy of pipobroman ...
- Pipobroman information including symptoms, causes, diseases, symptoms, treatments, and other medical and health issues. ... Introduction: Pipobroman Description of Pipobroman Pipobroman: An antineoplastic agent that acts by ...
Related Pictures